Key Takeaways
- Strong quarter, guidance intact: Consolidated revenue grew 34% YoY, with management reaffirming 20% revenue growth and profitability outpacing revenue for FY27.
- Jammu crosses breakeven: The Jammu facility posted its first positive EBITDA of ₹1 crore to ₹1.5 crore in Q1, with revenue of ~₹107 crore and healthy season still ahead from Q2.
- Volume is the engine: Of the 34% revenue growth, ~20–22% was volume growth at manufacturing capability level, with the remainder from favorable product/sales mix and pricing.
- Margin story is a Jammu story: Non-Jammu margin runs at ~20% while Jammu sits at 1–1.5%, pulling consolidated margin to ~16%; management sees Jammu reaching 17–18% margin, which would lift the consolidated profile.
- What to watch next quarter: Whether Jammu's ramp continues into the healthy season, whether gross margin holds near 35.5%, and whether management signals any upgrade to the 20%-plus growth guidance.
Jammu Ramp-Up
- Revenue trajectory: Jammu posted Q1 revenue of ~₹107 crore versus ~₹90 crore in Q4 FY26, with management stating the ramp-up is pacing as expected. Q1 typically carries seasonal impact, with the healthy season starting from Q2 onwards.
- Profitability inflection: Jammu achieved positive EBITDA of ₹1 crore to ₹1.5 crore this quarter, crossing the breakeven line for the first time.
- Optimum scale: Jammu plant optimum revenue is anticipated at ₹1,400 crore at utilization of 65% to 70%, with asset turns expected north of 3x at optimum level.
- Margin convergence: Once Jammu crosses breakeven, its margin profile will move in line with the base business; management expects Jammu to reach 17% to 18% margin, which from a base of 16% should upgrade the consolidated margin by 2% to 3% when Jammu starts giving contributing margin.
- Revenue milestone: Jammu can cross the ₹1,000 crore revenue mark once onboarding of countries, products, and customers completes; by end of this financial year, the company may have product approvals from different markets for Jammu.
Lokesh Bhasin: "Jammu, Jammu ramp-up is pacing up the way we expected. So, we should also consider that normally quarter one, there is a seasonal impact of the entire year. And from, see, from Q2 onwards the normal healthy season start picking up."
Segment Performance
- CDMO growth: 32% YoY growth driven by expanding product portfolio, addition of new customers, and deeper engagement with existing customers resulting in higher wallet share.
- Branded generic growth: 39% YoY growth supported by continued traction across key markets; management sees branded generic as a significant opportunity over the medium and long term to diversify revenue base and strengthen presence across key markets.
- No conflict between segments: From a plant perspective, branded generic business is treated as a normal CDMO customer, with no additional or special treatment.
- Sharon performance: Sharon had a seasonal impact on performance this quarter; full-year expectation is continued growth in line with organic business expectations, in the early teens.
Lokesh Bhasin: "So, from a plant perspective, from a manufacturing capability business, this our branded generic business is just considered as a normal CDMO customer by our plant. So, from that particular viewpoint, there is no, I would say, additional treatment or any special treatment for our branded generic business."
Margins & Cost Structure
| Margin component | Level |
|---|---|
| Consolidated margin | ~16% |
| Non-Jammu margin | ~20% |
| Jammu margin | 1% to 1.5% |
| Gross margin (Q1) | ~35.5% |
- Gross margin dip: YoY dip of 1% to 1.5% attributed to overall business mix changes, described as normal course of business. Full-year gross margin expected to maintain around 35.5% plus/minus 2%.
- Other expenses: Percentage basis slightly reduced YoY; absolute increase commensurate with operations growth. Slight increase in logistics costs due to conflict, duly factored in and not material.
- Margin guidance: Management maintained margin guidance at 15% to 16% plus-minus 2%; once Jammu starts giving good EBITDA margin, overall margin at 15% to 16% level should expand.
- Pricing environment: This quarter prices trended toward the increase side; management able to pass through pricing to customers at a certain level.
Vinay Lohariwala: "Assuming 20% is very high expectation. I think it 17%, 18% is the fair number."
Growth Drivers & Strategy
- Volume growth: 20% to 22% volume growth at overall manufacturing capability level came from existing capabilities contributing to growth, optimization of resources, and operating leverage benefits.
- Volume guidance: Management maintained volume growth guidance at north of 20% on volume basis, and is very confident of 20% plus volume growth in the coming period.
- Strategic priorities: Improving capacity utilization, expanding complex dosage form capabilities, strengthening R&D platforms, deepening customer relationships, and expanding branded generic presence.
- Future expansion: Likely in tranches of ₹200 crore to ₹250 crore rather than large single investments; will expand in saturated categories (general Baddi portfolio, core Baddi portfolio) and open new dosage forms or therapeutic categories where currently not present.
- Baddi plot: New plot bought last year; plan remains on same line, still being firmed up; will come to market with more concrete plan when finalized.
Vinay Lohariwala: "Both the engine can help the company to grow or maintain this 20% plus CAGR in the future."
Capex & Investment
- Maintenance capex: FY27 and FY28 maintenance capex expected at ₹20 crore to ₹25 crore.
- Growth capex: FY27 and FY28 growth capex expected at ₹20 crore to ₹30 crore.
- R&D spend: Expected to remain in 0.7% to 1% of total revenue range.
- Cash conversion cycle: Expected to be maintained at 90 days plus/minus 10 days at group level.
- Semaglutide development: Status is "as is" from last con-call; development and plant team working on batches, closely watching.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20% revenue growth, profitability outpacing revenue | FY27 |
| Volume growth | North of 20% on volume basis | FY27 |
| Margin | 15% to 16% plus-minus 2% | FY27 |
| Gross margin | ~35.5% plus/minus 2% | FY27 |
| Jammu revenue | ₹1,400 crore optimum at 65–70% utilization | No date |
| Jammu margin | 17% to 18% margin profile | No date |
| Jammu approvals | Product approvals from different markets | By end of FY27 |
| Maintenance capex | ₹20 crore to ₹25 crore | FY27 and FY28 |
| Growth capex | ₹20 crore to ₹30 crore | FY27 and FY28 |
| R&D spend | 0.7% to 1% of total revenue | FY27 |
| Cash conversion cycle | 90 days plus/minus 10 days | Group level, ongoing |
| Sharon growth | Early teens, in line with organic business | FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹470.9 crores, +34% YoY |
| EBITDA | ₹75.1 crores, +33% YoY, margin of 16% |
| Profit after tax | ₹44.1 crores, +42% YoY |
| Gross margin | ~35.5%, down 1% to 1.5% YoY; full-year expected at 35.5% plus/minus 2% |
| CDMO revenue | ₹328.7 crores, +32% YoY |
| Branded generic revenue | ₹142.2 crores, +39% YoY |
| Export share of revenue | 32% of consolidated revenue |
| Volume growth guidance | 20% plus on volume basis, maintained for FY27 |
| Jammu facility revenue | ~₹107 crores, up from ~₹90 crores in Q4 FY26 |
| Jammu facility utilization | ~25% to 30% on an annualized basis |
| Jammu facility EBITDA | ₹1 crore to ₹1.5 crores, first positive quarter |
| Jammu optimum revenue potential | ₹1,400 crores at 65% to 70% utilization |
| Cash conversion cycle | 90 days, plus/minus 10 days at group level |
| R&D spend | ~0.7% to 1% of total revenue |
| Maintenance capex | ₹20 crores to ₹25 crores annually for FY27 and FY28 |
| Growth capex | ₹20 crores to ₹30 crores annually for existing capability augmentation or debottlenecking |